Abivax stock surged 39.9% after releasing new data on its ulcerative colitis drug, obefazimod. The data suggests malignancies were in line with normal UC patient levels, and over 37% of non-responders achieved remission with a 50mg dose after 10 months.
Abivax shares surged 36% after new Phase 3 trial data showed its drug obefazimod provided clinically meaningful improvements for adults with moderate to severe ulcerative colitis, including non-responders, and confirmed a favorable safety profile.
Abivax shares dropped 43.6% after its ulcerative colitis drug, obefazimod, showed a cancer signal in trial data. While efficacy was met, the presence of cancer cases, particularly on the higher dose, has raised concerns and led to a downgrade by analysts, impacting potential takeover talks.
Abivax shares dropped 40% after reporting efficacy data for its ulcerative colitis drug, obefazimod, alongside cancer cases. Analysts cite the 'cancer signal' as a significant overhang, complicating potential takeover talks.
Abivax shares dropped 37% after reporting data on its ulcerative colitis drug, obefazimod. While the drug showed efficacy, the presence of cancer cases, particularly on the higher dose, raised concerns and led analysts to downgrade the stock, complicating potential takeover talks.
Abivax shares dropped 32% after reporting new data for its ulcerative colitis drug, obefazimod. While the drug showed efficacy, the emergence of cancer cases in patients, particularly on the higher dose, has raised concerns and led to a stock downgrade, complicating potential takeover talks.
